Acquisition of a U.S. podiatry clinic platform
First written in FY2024-Q3. 4 of 7 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- 2026-07-30AdvancedEarnings
「米国における高単価な下肢静脈疾患クリニックの患者数増加やOBLを運営するVascular Specialists社の新規連結影響により」
米国下肢静脈疾患クリニックの患者数増加と、OBL運営会社の新規連結が医療機関セグメントの売上収益に寄与した。 - FY2026RestatedAnnual report
「Overseas, while roll-up M&A in the U.S. podiatry field expanded the business, we strategically proceeded with measures such as closing unprofitable sites to improve the earnings structure.」
Roll-up M&A in U.S. podiatry continues alongside efforts to close unprofitable sites. - 2026-04-30AdvancedFinancial results presentation
「In February 2026, we made Vascular Specialists, LLC, which operates an OBL in Illinois, a consolidated subsidiary.」
米国足病クリニック基盤に、イリノイ州のOBL運営会社を新たに加えている。 - FY2026-H1AdvancedAnnual report
「Overseas, roll-up M&A in the U.S. podiatry field remained solid, but revenue declined slightly as one-time revenue from the collection of historical operating receivables recognized in the previous interim consolidated accounting period fell away.」
Roll-up M&A in U.S. podiatry continues to progress steadily, expanding the acquired platform. - FY2025-H1AdvancedAnnual report
「Overseas revenue increased as a result of the acquisition of the U.S. podiatry business in January 2024, and segment revenue for the current interim consolidated accounting period was ¥8,903 million, up 73.1% year on year.」
The U.S. podiatry acquisition contributed specifically to higher overseas revenue and interim healthcare institution segment revenue. - FY2024Cited as achievedAnnual report
「At a Board of Directors meeting held on 22 December 2023, we resolved, through our wholly owned subsidiary CUC America Inc., to acquire a 79.35% interest in Albaron Podiatry Holdings, LLC, which operates “Beyond Podiatry” and has a platform for managing podiatry clinics in the United States, making it a consolidated subsidiary. The interest was acquired on 6 January 2024.」
The completed acquisition of a 79.35% interest in the U.S. podiatry and venous disease clinic business is confirmed in the full-year report. - FY2024-Q3AchievedAnnual report
「At a Board of Directors meeting held on 22 December 2023, we resolved to acquire, through our wholly owned subsidiary CUC America Inc. (“CUC America”), a 79.35% interest in Albaron Podiatry Holdings, LLC (“Albaron Podiatry”), which operates “Beyond Podiatry” and has a platform for managing podiatry clinics in the United States, making it a consolidated subsidiary. The interest was acquired on 6 January 2024 Japan Standard Time.」
The company completed the acquisition of a 79.35% interest in Albaron Podiatry, a U.S. podiatry clinic operator. The purchase price was approximately US$69.1 million for the interest and US$1.3 million in related costs. The platform operates more than 30 clinics staffed by more than 50 podiatrists and venous disease specialists.